In targeted therapy for lung cancer, especially EGFR and ALK inhibitors, may damage the glomeruli, renal tubules or any other part of the nephron, leading to deterioration of renal function and the appearance of various clinical symptoms such as AKI, electrolyte disturbances, nephrotic syndrome and glomerulonephritis (12). This evidence concerns the gene EGFR and glomerulonephritis.